Gary L. Rosner, ScD, on Bayesian Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame healt...

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for...

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

May

Today In Oncology

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?

FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer

More From the FDA ODAC Votes on Agents for Pretreated Hepatocellular Carcinoma and Gastric Cancer

Increased Loneliness Among Patients With Cancer During the COVID-19 Pandemic May Affect Symptom Burden

One vs Two Doses of the BNT162b2 COVID-19 Vaccine in Patients With Cancer: Immunogenicity and Efficacy